{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001013932,0.0006002625,0.001436489,0.0004714144,0.0009065908,0.00002987142,0.0009715845,0.0005695614,0.00004131265],"category_scores_gemma":[0.004238826,0.0004137187,0.0001680614,0.001703642,0.001707611,0.0001537162,0.001048716,0.001132561,0.0001251026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128621,"about_ca_system_score_gemma":0.000747117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004993032,"about_ca_topic_score_gemma":0.00160756,"domain_scores_codex":[0.9953346,0.0002128643,0.001094124,0.001332652,0.0006974309,0.001328379],"domain_scores_gemma":[0.993718,0.002532617,0.0006046728,0.001996417,0.001029406,0.00011885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1201645,0.02135406,0.2877764,0.0007361231,0.009339417,0.006065237,0.01761688,0.0001650356,0.02358657,0.0006436622,0.1560419,0.3565101],"study_design_scores_gemma":[0.2095221,0.08438363,0.31388,0.0009587323,0.001410834,0.0001687613,0.01384235,0.0006993099,0.006390626,0.001124041,0.3661595,0.001460124],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694259,0.001539929,0.0001097047,0.01876585,0.0006614402,0.006933155,0.000986919,0.0009387322,0.0006383331],"genre_scores_gemma":[0.989993,0.001212693,0.001384394,0.0008039052,0.0002767016,0.002945234,0.0007750448,0.0001363232,0.00247275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.35505,"threshold_uncertainty_score":0.9998314,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03270754885638696,"score_gpt":0.3655740603058458,"score_spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}